The metabolic peptide market is increasingly organized around mechanism combinations rather than single-compound narratives. Incretin-based therapies remain the center of gravity, but the practical question is becoming more specific: which pathway, which tradeoff, and which access reality applies to a given person.
For Peptivius, this kind of update belongs in the research layer. It should not change a plan automatically. It should help the user understand why similar compounds can differ in tolerability, availability, maintenance strategy, and real-world complexity.
In a future personalized version, this story could be matched against the user profile, ranked peptides, current plan, and Daily Log history to produce a tighter relevance note.